Real-time monitoring of ctDNA is a promising tool for tailoring adjuvant treatment, given the established role of molecular residual disease in predicting DFS after radical surgery for EGFR-mutated tumours [45], but it is still far from being implemented in clinical practice, as discussed before. The gene discussed is EGFR; the disease is neoplasm.